Reactome | BRD7 promotes EP300-mediated acetylation of TP53

BRD7 promotes EP300-mediated acetylation of TP53

Stable Identifier

R-HSA-5628871

Type

Reaction [transition]

Species

Homo sapiens

Compartment

nucleoplasm

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

Gene expression (Transcription) (Homo sapiens)

- RNA Polymerase II Transcription (Homo sapiens)
  - Generic Transcription Pathway (Homo sapiens)
    - Transcriptional Regulation by TP53 (Homo sapiens)
      - Regulation of TP53 Activity (Homo sapiens)
        
        Regulation of TP53 Activity through Acetylation (Homo sapiens)
        
        BRD7 promotes EP300-mediated acetylation of TP53 (Homo sapiens)

General

SBML | | PDF

SVG | | PPTX | SBGN

BRD7 promotes EP300-mediated acetylation of TP53

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

BRD7 promotes EP300 (p300)-mediated acetylation of TP53 on lysine residue K382, which enhances binding of TP53 to its target promoters. Also, BRD7 induces EP300-mediated acetylation of histone 3 on lysine residue K10 (also labeled in literature as K9), creating the H3K9 active chromatin mark at CDKN1A and MDM2 promoters (Drost et al. 2010), and possibly other TP53 promoters co-regulated by BRD7, such as SERPINE1, TIGAR, TNFRSF10C and NDRG1.

Literature References

PubMed ID	Title	Journal	Year
20228809	BRD7 is a candidate tumour suppressor gene required for p53 function Tocco, F, Del Sal, G, Drost, J, Elkon, R, Holstege, H, Kerkhoven, R, Mantovani, F, Agami, R, Jonkers, J, Comel, A, Voorhoeve, PM	Nat. Cell Biol.	2010